Scotia Capital Inc. Immuno Gen, Inc. Transaction History

Scotia Capital Inc.

$17.8 Billion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$12.46 - $29.95 $51,472 - $123,723	4,131 Added 27.58%	19,110 $566,000
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $24,925 - $35,150	1,769 Added 13.39%	14,979 $237,000
Q2 2023 Aug 03, 2023	SELL	$3.75 - $20.05 $11,250 - $60,150	-3,000 Reduced 18.51%	13,210 $249,000
Q2 2022 Aug 05, 2022	BUY	$3.15 - $5.76 $107 - $195	34 Added 0.21%	16,210 $73,000
Q1 2022 May 09, 2022	BUY	$4.26 - $7.48 $1,516 - $2,662	356 Added 2.25%	16,176 $77,000
Q4 2021 Feb 11, 2022	SELL	$4.75 - $7.5 $27,953 - $44,137	-5,885 Reduced 27.11%	15,820 $117,000
Q3 2021 Nov 12, 2021	SELL	$5.02 - $6.59 $577 - $757	-115 Reduced 0.53%	21,705 $123,000
Q1 2021 May 06, 2021	SELL	$6.5 - $10.53 $260 - $421	-40 Reduced 0.18%	21,820 $177,000
Q4 2020 Feb 11, 2021	BUY	$3.7 - $7.66 $5,853 - $12,118	1,582 Added 7.8%	21,860 $141,000
Q3 2020 Nov 12, 2020	SELL	$3.45 - $4.89 $7,096 - $10,058	-2,057 Reduced 9.21%	20,278 $73,000
Q2 2020 Aug 11, 2020	BUY	$3.32 - $5.34 $16,600 - $26,700	5,000 Added 28.84%	22,335 $104,000
Q1 2020 May 15, 2020	SELL	$2.12 - $6.8 $657 - $2,108	-310 Reduced 1.76%	17,335 $59,000
Q4 2019 Feb 13, 2020	BUY	$2.25 - $5.8 $2,430 - $6,264	1,080 Added 6.52%	17,645 $90,000
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $12,050 - $29,550	5,000 Added 43.23%	16,565 $45,000
Q4 2018 Feb 11, 2019	BUY	$3.94 - $9.7 $2,758 - $6,789	700 Added 6.44%	11,565 $55,000
Q1 2018 May 15, 2018	SELL	$6.7 - $12.95 $4,690 - $9,065	-700 Reduced 6.05%	10,865 $114,000
Q4 2017 Feb 13, 2018	SELL	$5.07 - $7.92 $1,622 - $2,534	-320 Reduced 2.69%	11,565 $74,000
Q3 2017 Nov 14, 2017	SELL	$5.4 - $8.47 $9,180 - $14,399	-1,700 Reduced 12.51%	11,885 $91,000
Q2 2017 Aug 15, 2017	BUY	N/A	13,585	13,585 $97,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Scotia Capital Inc., based on Form 13F filings with the SEC.

News

Stay updated on Scotia Capital Inc. with notifications on news.

Account